Total Payments
$5,414
2024 Payments
$214.86
Companies
19
Transactions
34
Medicare Patients
497
Medicare Billing
$101,651
Payment Breakdown by Category
Research$3,084 (57.0%)
Consulting$1,375 (25.4%)
Food & Beverage$777.99 (14.4%)
Education$176.97 (3.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,084 | 1 | 57.0% |
| Consulting Fee | $1,375 | 1 | 25.4% |
| Food and Beverage | $777.99 | 30 | 14.4% |
| Education | $176.97 | 2 | 3.3% |
Payments by Type
Research
$3,084
1 transactions
General
$2,330
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $3,124 | 2 | $0 (2024) |
| Seagen Inc. | $1,375 | 1 | $0 (2020) |
| Janssen Biotech, Inc. | $152.87 | 9 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $104.24 | 1 | $0 (2017) |
| Seattle Genetics, Inc. | $104.15 | 1 | $0 (2019) |
| Genentech USA, Inc. | $101.27 | 4 | $0 (2024) |
| BioNTech SE | $81.46 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $72.73 | 1 | $0 (2023) |
| Genentech, Inc. | $63.00 | 1 | $0 (2022) |
| Incyte Corporation | $60.39 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $214.86 | 5 | BioNTech SE ($81.46) |
| 2023 | $3,171 | 3 | Eli Lilly and Company ($3,084) |
| 2022 | $63.00 | 1 | Genentech, Inc. ($63.00) |
| 2021 | $32.68 | 1 | GE HEALTHCARE ($32.68) |
| 2020 | $1,375 | 1 | Seagen Inc. ($1,375) |
| 2019 | $132.65 | 3 | Seattle Genetics, Inc. ($104.15) |
| 2018 | $101.00 | 7 | Janssen Biotech, Inc. ($73.80) |
| 2017 | $323.86 | 13 | Millennium Pharmaceuticals, Inc. ($104.24) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $40.08 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Oncology | ||||||
| 10/12/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $81.46 | General |
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 05/29/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $16.83 | General |
| 12/22/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Education | In-kind items and services | $72.73 | General |
| Category: ONC | ||||||
| 06/23/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Oncology | ||||||
| 04/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $3,083.75 | Research |
| Study: EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 06/05/2022 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $63.00 | General |
| 09/07/2021 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $32.68 | General |
| 08/13/2020 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 11/05/2019 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Oncology | ||||||
| 05/29/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $104.15 | General |
| 04/11/2019 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: Oncology | ||||||
| 12/04/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Oncology | ||||||
| 06/13/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Oncology | ||||||
| 05/17/2018 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Oncology | ||||||
| 04/24/2018 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Oncology | ||||||
| 04/10/2018 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Oncology | ||||||
| 03/14/2018 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $14.70 | General |
| 01/30/2018 | Janssen Biotech, Inc. | ZYTIGA (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Oncology | ||||||
| 11/16/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.16 | General |
| Category: Hematology/Oncology | ||||||
| 10/26/2017 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: BioOncology | ||||||
| 10/03/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.98 | General |
| Category: Hematology/Oncology | ||||||
| 09/12/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $3,084 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 132 | 232 | $244,400 | $23,452 |
| 2022 | 4 | 113 | 218 | $148,225 | $25,700 |
| 2021 | 5 | 131 | 270 | $107,749 | $31,956 |
| 2020 | 4 | 121 | 201 | $90,273 | $20,542 |
Total Patients
497
Total Services
921
Medicare Billing
$101,651
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 36 | 99 | $116,081 | $11,783 | 10.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 69 | 106 | $89,079 | $7,486 | 8.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $39,240 | $4,183 | 10.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 12 | 55 | $8,800 | $8,747 | 99.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 29 | 68 | $63,556 | $8,309 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 59 | 82 | $59,644 | $6,698 | 11.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $16,225 | $1,945 | 12.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 18 | 76 | $12,160 | $12,177 | 100.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 48 | 90 | $36,678 | $7,699 | 21.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 23 | 61 | $35,327 | $7,662 | 21.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $18,283 | $3,587 | 19.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 20 | 21 | $5,301 | $831.60 | 15.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 71 | $38,314 | $8,450 | 22.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 32 | 52 | $19,315 | $4,680 | 24.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 46 | 58 | $16,544 | $3,746 | 22.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $16,100 | $3,667 | 22.8% |
About Mridula George
Mridula George is a Internal Medicine healthcare provider based in New Brunswick, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2012. The National Provider Identifier (NPI) number assigned to this provider is 1285997569.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mridula George has received a total of $5,414 in payments from pharmaceutical and medical device companies, with $214.86 received in 2024. These payments were reported across 34 transactions from 19 companies. The most common payment nature is "" ($3,084).
As a Medicare-enrolled provider, George has provided services to 497 Medicare beneficiaries, totaling 921 services with total Medicare billing of $101,651. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location New Brunswick, NJ
- Active Since 06/21/2012
- Last Updated 11/26/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1285997569
Products in Payments
- TUKYSA (Drug) $1,375
- DARZALEX (Biological) $118.96
- VELCADE (Drug) $104.24
- Trodelvy (Drug) $72.73
- JAKAFI (Drug) $60.39
- Truqap (Drug) $30.00
- VENCLEXTA (Biological) $23.51
- YONDELIS (Drug) $19.24
- Halaven (Drug) $19.02
- Blincyto (Biological) $17.39
- KEYTRUDA (Biological) $17.07
- TECENTRIQ (Biological) $16.57
- KISQALI (Drug) $15.10
- ZYTIGA (Drug) $14.67
- Orserdu (Drug) $14.18
- IMBRUVICA (Drug) $12.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New Brunswick
Dr. Reynold Panettieri, Md, MD
Internal Medicine — Payments: $969,147
Internal Medicine $969,147
Dr. Stephen Marcella, Md, MD
Internal Medicine — Payments: $331,029
Internal Medicine $331,029
Dr. Ashok Chaudhary, Md, MD
Internal Medicine — Payments: $119,190
Internal Medicine $119,190
Dr. Steven Peskin, M.d, M.D
Internal Medicine — Payments: $95,760
Internal Medicine $95,760
Soko Setoguchi Iwata, Md, Drph, MD, DRPH
Internal Medicine — Payments: $69,504
Internal Medicine $69,504
David Kountz
Internal Medicine — Payments: $47,346
Internal Medicine $47,346